Novalung GmbH, which specialises in solutions for respiratory failure, was absorbed into Xenios AG on 30 August 2019. Processes will be streamlined as a result and the company will become more closely aligned with the parent company Fresenius Medical Care.
Novalung was established in 2003 and specialises in the treatment of respiratory failure. The company has been part of Xenios AG since 2013.
Since the end of 2016, Xenios has been part of Fresenius Medical Care, the leading provider of products and services for people with kidney diseases. “This merger will produce more streamlined processes within Xenios and can in turn impact positively on our response times to customer enquiries and orders,” explains Dr. Andreas Terpin, CEO of Xenios AG. “At the same time we are putting in place the conditions for the ongoing integration of our products and therapies within the parent company Fresenius Medical Care.”
While expansion of the product portfolio is ongoing, proven elements will remain under the umbrella of Xenios. “Novalung” will be retained as an established brand in the intensive care market and developed further with the support of the parent company. Novalung is to serve in future as a key pillar in the area of multi-organ support within the Fresenius Medical Care concept.
“Xenios will continue to offer and produce the Novalung product and therapy portfolio related to lung support. Only the name of the legal manufacturer on the product packaging will change. All existing contact persons remain and will continue to guarantee high quality in order processing,” commented Dr. Jürgen Böhm, Chief Medical Officer of Xenios.
The merger was notarized and entered in the commercial register in mid-August.
